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In this study we analyzed the expression levels of markers of epithelial-to-mesenchymal transition
(EMT) in several papillary thyroid carcinomas (PTCs) and the relation with tumor genotypes and clini-
copathological characteristics. The role of fibronectin-1 (FN1) was investigated by analyzing the effects of
FN1 silencing in two human thyroid cancer cell lines.
Most of EMT markers were significantly over-expressed in a group of 36 PTCs. In particular, FN1mRNA
levels were higher in tumor vs non-tumor tissue (117.3, p < 0.001) and also in aggressive and BRAFV600E
samples. Similar results were observed (and confirmed at the protein level) when FN1 expression was
analyzed in a validation group of 50 PTCs and six lymph node (LN) metastases. Silencing of FN1 in TPC-1
and BCPAP thyroid cancer cells significantly reduced proliferation, adhesion, migration, and invasion in
both cell lines.
Collectively, our data indicate that FN1 overexpression is an important determinant of thyroid cancer
aggressiveness.
© 2016 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The incidence of differentiated thyroid carcinoma (DTC) has
increased over the past decade (Udelsman and Zhang, 2014; Mehra
et al., 2015). Although the majority of patients have an excellent
prognosis, the management of invasive tumors and/or distant
metastases is still a major clinical challenge, especially those that
are unresponsive to radioiodine therapy (Schlumberger et al., 2007;; DTC, differentiated thyroid
l-to-mesenchymal transition;
-1; IR, intermediate risk; LN,
polymerase 1; PTC, papillary
ular-variant PTC; TLDA, Taq-
ciences, University “Magna
opa, 88100, Catanzaro, Italy.
rved.Carneiro et al., 2015). For these tumors, improved understanding of
the molecular alterations responsible for their aggressive behavior
could lead to the development of new treatment options (Bulotta
et al., 2016).
The epithelial-to-mesenchymal transition (EMT) is an essential
step in cancer progression: it provides cancer cells with the ca-
pacity to migrate from the primary tumor, invade surrounding
tissues, and reach distant sites (Thiery and Sleeman, 2006; Huber
et al., 2005). Vasko et al. (2007) showed that an expression pro-
file consistent with EMT is common in invasive papillary thyroid
carcinomas (PTCs) and highlighted the roles played in this process
by vimentin and other extracellular matrix (ECM) proteins. Sub-
sequently, another EMT marker, periostin, was reported to be
overexpressed in PTC, and its mRNA levels were positively corre-
lated with extrathyroidal invasion, distant metastasis, and higher
grade staging (Puppin et al., 2008). Interestingly, ECM alterations
have been described as a consequence of the BRAFV600E mutation
(Nucera et al., 2011), the most common genetic alteration detected
in human PTCs, and increasing bodies of in vitro and in vivo data
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and aggressive behavior in thyroid cancer (Durante et al., 2007;
Puxeddu et al., 2008; Nucera et al., 2009; Knauf et al., 2011).
In this study, we investigated the gene expression levels of 27
EMT markers in group of 36 PTCs classified as intermediate or low
risk (IR or LR) tumors according to current criteria published by the
American Thyroid Association (ATA) (Haugen et al., 2016). Fibro-
nectin-1 (FN1), a fundamental component of the ECM, was the
marker most strikingly upregulated in IR-PTCs relative to those
classified as LR-PTC, and this finding was validated in a second
series of PTCs, which also included metastatic lymph node (LN)
tissues. Small-interfering RNA-mediated silencing of FN1 in two
human thyroid cancer cell lines clearly demonstrated the involve-
ment of FN1 in the viability, adhesion, migration, and invasive
properties of thyroid cancer cells.2. Materials and methods
2.1. Collection of thyroid tissues
The study protocol was preapproved by the institutional ethics
committee. Tumor tissues and normal thyroid tissues were pro-
spectively collected from consenting 86 patients consecutively
subjected to total thyroidectomy for sporadic PTC at the “Sapienza”
University Hospital of Rome between 2009 and 2014. Tissue sam-
ples were excluded if tumor sample cellularity was less than 60%,
and/or if normal thyroid tissue from the uninvolved lobe exhibitedTable 1
Clinical data of PTC patients at the time of primary treatment.
Clinicopathological featuresa Screening gro
Age at diagnosis
Patients <45 yr 17 (47.2)
Patients 45 yr 19 (52.8)
Gender
Male 11 (30.6)
Female 25 (69.4)
Tumor size
 1 cm 27 (75.0)
< 1 cm 9 (25.0)
Multifocalityb
Yes 11 (30.6)
No 25 (69.4)
Extrathyroidal extensionc
Yes 14 (38.9)
No 22 (61.1)
Lymph node metastasesb
Yes 11 (30.6)
No 25 (69.4)
ATA riskb,d
Low 12 (33.3)
Intermediate 24 (66.7)
BRAF mutational status
wt 15 (41.7)
V600E 20 (55.6)
V600_K601 > E 1 (2.8)
Histological variant
PTC-CL 31 (86.1)
PTC-FV 5 (13.9)e
PTC-other 0
Validation group includes 6 lymph nodes.
Abbreviations: ATA, American Thyroid Association; PTC, papillary thyroi
wild-type.
a Results are reported as numbers (%) of patients in the screening and
b Data not available for one patient.
c Data not available for two patients.
d American Thyroid Association risk stratification staging system (Hau
e One sample showed extrathyroidal extension.
f Three samples showed extrathyroidal extension.signs of inflammation or other types of disease. All 86 PTCs were
also used to study the expression of thyroid-specific differentiation
markers, and those results have been described elsewhere
(Sponziello et al., 2015; Rosignolo et al., 2015).
Samples of tumor tissue (n ¼ 86, 36 in the screening group and
50 in the validation group), LN metastases (n ¼ 6, all from cases in
the validation series) and normal thyroid tissue (n ¼ 42, including
18 in the screening group and 24 in the validation group) were
collected and immediately frozen after thyroidectomy. For each
tumor, the risk of recurrencewas classified as LR or IR in accordance
with the 2015 ATAGuidelines for theManagement of Adult Patients
with Thyroid Nodules and Differentiated Thyroid Cancer (Haugen
et al., 2016). BRAF mutational status was determined by Sanger
sequencing, as previously described (Passon et al., 2015). PTC his-
totypes were determined by histopathological examination. The
clinical and pathological characteristics of the screening and vali-
dation groups are summarized in Table 1.2.2. Extraction of RNA and gene expression studies
Total RNA was isolated from tissues using TRIzol reagent
(Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the
manufacturer’s protocol, quantified with a NanoDrop Spectropho-
tometer (Thermo Fisher Scientific), and reverse-transcribed with a
High Capacity cDNA Reverse Transcription kit (Thermo Fisher Sci-
entific). The expression of 27 EMT-related genes was then assessed
using a TaqMan Low Density Array (TLDA), and mRNA levels of FN1up (n ¼ 36) Validation group (n ¼ 56)
29 (51.8)
27 (48.2)
20 (35.7)
36 (64.3)
42 (75.0)
14 (25.0)
10 (17.9)
35 (62.5)
24 (42.9)
30 (53.6)
24 (42.9)
31 (55.4)
13 (23.2)
42 (75.0)
16 (28.6)
40 (71.4)
0
45 (80.4)
9 (16.1)f
2 (3.6)
d carcinoma; PTC-CL, classic PTC; PTC-FV, follicular-variant PTC; wt,
validation groups.
gen et al., 2016).
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(Sponziello et al., 2013).
All qPCR assays were performed on a 7900 HT Fast Real-time
PCR System (Thermo Fisher Scientific), Ct values were calculated
with SDS 2.4 software (Thermo Fisher Scientific), and data were
analyzed with RQ Manager 1.2.1 software (Thermo Fisher Scienti-
fic). Final results were determined by the comparative 2DDCt
method using b-actin as endogenous control.
After all analysis, expression levels in normal thyroids were
averagedand indicated as 1, and the expression levels in cancerwere
expressed as the ratio to the levels of average in normal thyroids.2.3. Protein extraction and western blot analysis
Total proteins were extracted as previously described
(D’Agostino et al., 2012; Sponziello et al., 2015). Extracts (30 mg of
protein) were run on a 5% or 12% SDS-PAGE gel, transferred to PVDF
membranes (VWR, Milan, Italy), blocked with TTBS/milk (TBS, 1%
Tween 20, 5% non-fat dry milk) or TTBS/BSA (TBS, 1% Tween 20, 5%
BSA), and incubated overnight with affinity-purified anti-FN1
(Sigma Aldrich, Milan, Italy), anti-ERK1/2 (Cell Signaling, Danvers,
MA, USA), anti-phospho-ERK1/2 (Cell Signaling), and anti-b-actin
antibodies (Sigma Aldrich), diluted 1:1000, 1:1000, 1:2000, and
1:10000, respectively. The membranes were washed in TTBS and
incubated with horseradish peroxidase-conjugated anti-rabbit or
anti-mouse antibody (Transduction Laboratories, Lexington, KY,
USA) in TTBS/milk, diluted 1:5000 or 1:20000 respectively. The
protein was visualized by chemiluminescence using the Western
blot detection system ECL Plus (Perkin Elmer, Monza, Italy).2.4. Thyroid cancer cell lines, treatments, and FN1 silencing
TwohumanPTC cell lineswere used for in vitro experiments. TPC-
1 and BCPAP, characterized by RET/PTC1 rearrangement and
BRAFV600E mutation, respectively (Schweppe et al., 2008), were
cultured as previously described (Bulotta et al., 2013). Short tandem
repeat profiling was used to authenticate these cell lines. Immortal-
ized, non-tumorigenic Nthy-ori-3-1 (European Collection of
Authenticated Cell Culture) cells were grown in RPMI medium
(ThermoFisher Scientific) supplementedwith10% fetal bovine serum
(FBS, ThermoFisher Scientific), penicillin (100 IU/ml), streptomycin
(100 mg/ml), and amphotericin B (2.5 mg/ml) (Sigma Aldrich).
BCPAP cells were treated with the selective BRAFV600E inhibitor
PLX4032 (Vemurafenib, RG7204) (Selleck Chemicals, Houston, TX,
USA), as previously reported (Xing et al., 2011). Briefly, cells were
plated onto medium containing FBS 5% in 6 well plates (7  105/
well). Twenty-four hours later, PLX4032 (0.0, 0.01, 0.10, 0.30, 1.00,
and 3.00 mM) was added and plates incubated for 24 h. The inhi-
bition of BRAFV600E was confirmed by western blot analysis of
phospho-ERK1/2. Primary antibodies against ERK1/2 and b-actin
were used as controls.
For FN1 silencing, we used three different FN1 specific siRNA
(siFN1) (sequences 50e30: a. CAGUCAAAGCAAGCCCGGUUGUUAU;
b. GCAGUGGCUGAAGACACAAGGAAAU; c. GGGACUUCCUAU-
GUGGUCGGAGAAA). Cells were transiently transfected using Lip-
ofectamine RNAiMAX (ThermoFisher Scientific), in accordancewith
the manufacturer’s instructions. Cells were plated onto medium
containing FBS 10% in 6well plates (TPC-1,1.5 105/well and BCPAP
2  105/well) and had reached 60e80% confluence at the time of
transfection. Forty-eight hours after transfection, changes in FN1
protein expression were assessed with Western blot and immu-
nofluorescence assays. Cells transfected with Stealth RNAi Negative
Control Duplexes (ThermoFisher Scientific) were used as controls
(indicated as siCtrl) in all experiments.2.5. Immunofluorescence assay
After FN1 silencing, cells were fixed in 4% paraformaldehyde,
treated with Triton X-100, and processed for immunofluorescence
as described previously (Bulotta et al., 2006). Briefly, cells were
immunostained for FN1 using a monoclonal anti-FN1 antibody
(Sigma Aldrich) at 1:100 dilution and then incubated with Alexa
Fluor 555 anti-mouse antibody from Molecular Probes (Thermo
Fisher Scientific) at 1:800 dilution. Finally, cell DNA was stained
with Hoechst 33258 (ThermoFisher Scientific) and observed with a
Leica TC-SP2 confocal microscope.
2.6. Analysis of cell viability
Cell viability was evaluated by MTT (Maggisano et al., 2014) and
cell count assays (Celano et al., 2015). After FN1 silencing, two as-
says were performed as follows: (a) for MTT, TPC-1 and BCPAP cells
were seeded in 96 well plates, at a density of 3  103 or 6  103 for
well, respectively. After 24 h of incubation, culture medium was
replaced with fresh medium containing MTT, and its solubilized
product formazan was quantified with a microplate spectropho-
tometer (xMark, Biorad, Milan, Italy) at awavelength of 540 nm and
a reference wavelength of 690 nm; (b) for cell count, TPC-1 and
BCPAP cells were seeded in 12 well plates at a density of 1  104 or
2  104 for well, respectively, and incubated for 24 h. Viable cells
were counted in chamber slides (Countess, automated cell counter,
ThermoFisher Scientific) after Trypan blue staining. Results are
expressed as percentages over cells transfected with Stealth RNAi
Negative Control Duplexes (ThermoFisher Scientific), used as con-
trol (siCtrl).
2.7. Adhesion, migration and invasion assays
Adhesion assays were performed as previously described (Liu
et al., 2005; Bulotta et al., 2009). Briefly, after FN1 silencing,
5  104 cells were plated into 24 well plates coated with collagen I
(BD, Milan, Italy) and incubated for 1 h; then, unattached cells were
removed with PBS and adherent cells were fixed in 4% para-
formaldehyde for 15 min, stained with 0.1% Crystal Violet solution
for 10 min and washed with H2O. The stain was solubilized in 10%
acetic acid and cell attachment was quantified by measurement of
absorbance at 560 nm with xMark microplate spectrophotometer
(Biorad).
Cell migration was evaluated using Transwell inserts with 8 mm
pore (Constar, Euroclone, Milan, Italy), as previously described
(Bulotta et al., 2009). To assess invasiveness, Transwell inserts were
coated with Matrigel (BD). After silencing, 5  104 cells were sus-
pended in serum-free medium containing 1% BSA (for migration
assay) or 1% FBS (for invasion assay) and plated in the upper
chamber of the inserts. The bottom wells contained 600 mL of
mediumwith 10% FBS as a chemotactic agent. After incubation (6 h
and 24 h for migration and invasion assays, respectively), cells that
had not migrated were removed from the upper surface of the fil-
ters with cotton swabs, and the filters were fixed and stained with
Diff-Quick Stain (Bio Map, Monza, Italy). Two different operators
counted migrated and invasive cells in eight random microscopic
fields (magnification 10x) using an eyepiece with a counting grid.
Results are expressed as percentages over cells used as control
(siCtrl).
2.8. Statistical analysis
Results are expressed as mean ± standard deviations (SD). For
cell proliferation, migration, and invasion assays, we used a one-
way ANOVA followed by the Tukey-Kramer multiple comparisons
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to assess differences in gene expression levels between two groups
of samples; the Kruskal Wallis test, followed by Dunn’s multiple
comparisons test was used when three or more groups were
compared. P-values lower than 0.05 were considered statistically
significant. All statistical analyses were performed using GraphPad
Prism version 5.0 statistical software (GraphPad Software Inc., San
Diego, CA, USA).
3. Results
3.1. Expression levels of EMT genes in PTC
As shown in Table 1, the 36 PTCs in the screening group included
24 that classified as IR and 12 that were LR according to ATA criteria
(Haugen et al., 2016). These tumors were also characterized by the
presence or absence of the BRAFV600E mutation (Table 1). TLDA
analysis revealed that most of the EMT-related genes examined
were significantly overexpressed in tumor tissues compared with
levels observed in normal thyroid tissues (Table 2). The most sub-
stantial upregulation involvedmRNA levels for FN1 (increased 117.3
fold, p < 0.0001). Interestingly, the increase over normal levels was
even more striking when analysis was restricted to the following
subgroups: PTCs displaying the classic histotype (PTC-CL) (136 fold
increase vs normal thyroid tissue, p < 0.0001) (Supplemental
Table 1), IR-PTCs (148 fold, p < 0.0001) (Table 3), and PTCs
harboring the BRAFV600E mutation (148 fold, p < 0.001) (Table 4).
Subsequent experiments were thus focused on the expression of
FN1, extending our investigation to a second series of PTC tissues
(validation group), which included 42 IR-PTCs, 13 LR-PTCs, and 6 LN
metastases. Forty of these PTCs carried the BRAFV600E mutation.
Real-time PCR analysis showed that expression levels of FN1 were
significantly increased in tumors and LN metastases relative to
levels in normal tissues (p < 0.001 and p < 0.05, respectively)Table 2
mRNA expression of EMT markers in PTCs compared to normal tissues from the screeni
NT (n ¼ 18) PTC (n ¼ 36)
ECM degradation
COL5A1 e Hs00609088_m1 1 ± 0.52 10.97 ± 20.56
CTSB e Hs00947433_m1 1 ± 0.44 2.01 ± 0.10
ECM1 e Hs00189435_m1 1 ± 0.49 19.59 ± 36.42
LAMB3 e Hs00165078_m1 1 ± 0.88 86.25 ± 88.29
LOX e Hs00184700_m1 1 ± 0.52 1.43 ± 1.38
LOXL2 e Hs00158757_m1 1 ± 0.37 4.65 ± 5.89
MMP2 e Hs01548727_m1 1 ± 0.55 0.72 ± 0.59
MMP9 e Hs00234579_m1 1 ± 1.09 5.15 ± 13.78
PLAU e Hs01547054_m1 1 ± 0.45 16.66 ± 15.28
PLAUR e Hs00958880_m1 1 ± 0.72 7.88 ± 6.90
TIMP3 e Hs00165949_m1 1 ± 0.37 3.12 ± 12.72
ECM adhesion
CDH1 e Hs01023894_m1 1 ± 0.54 1.73 ± 2.11
CDH2 e Hs00983056_m1 1 ± 1.46 10.23 ± 16.04
CDH11 e Hs00901475_m1 1 ± 0.45 2.66 ± 3.19
CDH16 e Hs00187880_m1 1 ± 0.65 0.07 ± 0.09
FN1 e Hs00365052_m1 1 ± 0.49 117.27 ± 149.19
SPP1 e Hs00959010_m1 1 ± 1.19 3.93 ± 4.08
VIM e Hs00185584_m1 1 ± 0.41 1.14 ± 1.38
Transcription factors
SNAI1 e Hs00195591_m1 1 ± 0.45 0.53 ± 0.73
SNAI2 e Hs00950344_m1 1 ± 0.66 0.44 ± 0.34
SNAI3 e Hs01018996_m1 1 ± 0.57 2.55 ± 3.78
SPRY4 e Hs00229610_m1 1 ± 0.46 2.85 ± 2.05
STAT3 e Hs00374280_m1 1 ± 0.47 1.76 ± 1.49
TCF3 e Hs00413032_m1 1 ± 0.45 1.68 ± 1.19
TWIST1 e Hs01675818_s1 1 ± 0.47 1.44 ± 1.72
ZEB1 e Hs00232783_m1 1 ± 0.52 0.57 ± 0.38
ZEB2 e Hs00207691_m1 1 ± 0.51 0.75 ± 0.60
ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; ns, not significan(Fig. 1A). Again, a significant up-regulation was also found in the
subgroups of IR-PTCs (p < 0.001) and the BRAFV600E PTCs (p < 0.001)
(Fig. 1B, C). FN1 mRNA levels were increased in the PTC-CL sub-
group (p < 0.05 vs the follicular-variant PTC [PTC-FV] subgroup)
(Fig. 1D), in IR-PTCs (p < 0.05 vs LR-PTC), and in BRAFV600E PTC
(p < 0.01 vs BRAF-wt PTCs) (Fig. 1B, C). FN1 mRNA levels were not
significantly different in subgroups defined by the presence/
absence of extrathyroidal extension or of LN metastasis (data not
shown).
Western blot analysis was performed in the protein extracts
available from a representative series of IR-PTCs and their normal
counterpart. As shown in Fig. 2, higher levels of FN1 protein
expressionwere present in tumor tissue comparedwith the normal
counterpart.
3.1.1. Effects of siRNA-mediated silencing of FN1 on the
proliferation, adhesion, migration, and invasiveness of thyroid
cancer cells
Small interfering RNA-mediated FN1 silencing experiments
were done on TPC-1 and BCPAP cells, which show higher expres-
sion levels of FN1 than those in the non-tumorigenic cell line Nthy-
ori-3-1 (panel A of Fig. 3). Three specific siRNA were used (siFN1 a,
b, c). All three produced significant decreases in the levels of FN1
protein expression as compared with control siRNA (siCtrl)-trans-
fected or non-transfected cells (ctrl) (Fig. 3B, C). In cells transfected
with siFN1, cell viability decreased in TPC-1 and BCPAP cells
(~20e30%, p < 0.05, and ~40%, p < 0.01 vs siCtrl, respectively)
(Fig. 4). Silencing of FN1 in TPC-1 and BCPAP cell lines also signifi-
cantly reduced cell adhesion (~20%, p < 0.01, and ~30%, p < 0.01, vs
siCtrl, respectively), migration (~40%, p < 0.01, and ~50e60%
p < 0.001, vs siCtrl, respectively), and invasion (~40%, p < 0.001, vs
siCtrl) (Fig. 5). FN1 protein expression was also reduced in BCPAP
cells by treatment with the BRAFV600E kinase inhibitor, PLX4032
(Fig. 6).ng group.
p Value (Mann-Whitney test) p Value (Bonferroni correction)
0.0005 0.0135
<0.0001 0.0027
<0.0001 0.0027
<0.0001 0.0027
ns ns
<0.0001 0.0027
ns ns
0.0223 0.6021
<0.0001 0.0027
<0.0001 0.0027
ns ns
ns ns
<0.0001 0.0027
0.008 0.216
<0.0001 0.0027
<0.0001 0.0027
0.0003 0.0081
ns ns
<0.0001 0.0027
0.0002 0.0054
0.0063 ns
<0.0001 0.0027
0.0105 ns
0.0348 ns
ns ns
0.0002 0.0054
0.0158 ns
t; NT, normal thyroid tissues; PTC, papillary thyroid carcinoma.
Table 3
mRNA expression of EMT markers in tumor tissues of low risk PTC and intermediate risk PTC compared to normal tissues from the screening group.
NT (n ¼ 18) Low riska (n ¼ 12) Intermediate riska (n ¼ 24) p Value p Value (Dunn’s test)
(Kruskal Wallis test) NT vs low risk NT vs intermediate risk Low Risk vs intermediate risk
ECM degradation
COL5A1 1 ± 0.52 4.38 ± 7.48 14.27 ± 24.14 <0.0001 ns <0.001 <0.05
CTSB 1 ± 0.44 1.62 ± 0.92 2.20 ± 1.00 <0.0001 ns <0.001 ns
ECM1 1 ± 0.49 24.48 ± 42.60 17.15 ± 33.63 <0.0001 <0.001 <0.001 ns
LAMB3 1 ± 0.88 61.29 ± 53.45 98.73 ± 100.04 <0.0001 <0.01 <0.001 ns
LOX 1 ± 0.52 0.75 ± 0.64 1.77 ± 1.53 0.033 ns ns <0.05
LOXL2 1 ± 0.37 2.88 ± 3.04 5.52 ± 6.77 <0.0001 ns <0.001 ns
MMP2 1 ± 0.55 0.49 ± 0.40 0.83 ± 0.64 0.0358 <0.05 ns ns
MMP9 1 ± 1.09 7.92 ± 23.51 3.76 ± 4.32 0.0019 ns <0.01 <0.05
PLAU 1 ± 0.45 11.63 ± 13.48 19.17 ± 15.77 <0.0001 <0.01 <0.001 ns
PLAUR 1 ± 0.72 5.58 ± 5.35 9.04 ± 7.39 <0.0001 <0.01 <0.001 ns
TIMP3 1 ± 0.37 0.69 ± 0.55 4.33 ± 15.54 ns ns ns ns
ECM adhesion
CDH1 1 ± 0.54 1.35 ± 1.70 1.92 ± 2.30 ns ns ns ns
CDH2 1 ± 1.46 13.62 ± 24.69 8.53 ± 9.53 0.0002 <0.01 <0.001 ns
CDH11 1 ± 0.45 1.44 ± 1.40 3.28 ± 3.66 0.0009 ns <0.01 <0.05
CDH16 1 ± 0.65 0.08 ± 0.07 0.07 ± 0.10 <0.0001 <0.001 <0.001 ns
FN1 1 ± 0.49 55.31 ± 93.07 148.25 ± 163.47 <0.0001 ns <0.001 <0.05
SPP1 1 ± 1.19 2.26 ± 2.81 4.76 ± 4.40 <0.0001 ns <0.001 <0.05
VIM 1 ± 0.41 1.06 ± 1.01 1.19 ± 1.55 ns ns ns ns
Transcription factors
SNAI1 1 ± 0.45 0.43 ± 0.37 0.59 ± 0.86 0.0003 <0.01 <0.001 ns
SNAI2 1 ± 0.66 0.32 ± 0.29 0.50 ± 0.35 0.0002 <0.001 <0.05 ns
SNAI3 1 ± 0.57 2.99 ± 5.87 2.32 ± 2.18 0.0098 ns <0.01 ns
SPRY4 1 ± 0.46 2.99 ± 2.16 2.78 ± 2.03 0.0002 <0.001 <0.01 ns
STAT3 1 ± 0.47 1.37 ± 1.21 1.95 ± 1.61 0.0046 ns <0.01 ns
TCF3 1 ± 0.45 1.40 ± 1.04 1.82 ± 1.26 ns ns <0.05 ns
TWIST1 1 ± 0.47 0.68 ± 0.46 1.83 ± 2.00 ns ns ns <0.05
ZEB1 1 ± 0.52 0.45 ± 0.17 0.63 ± 0.45 0.0007 <0.01 <0.01 ns
ZEB2 1 ± 0.51 0.50 ± 0.45 0.86 ± 0.64 0.009 <0.01 ns ns
ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; ns, not significant; NT, normal thyroid tissues; PTC, papillary thyroid carcinoma.
a American Thyroid Association risk stratification staging system (2016).
Table 4
mRNA expression of EMT markers in tumor tissues of PTC BRAF-wt and PTC BRAFV600E compared to normal tissues from the screening group.
NT (n ¼ 18) BRAF-wt (n ¼ 15) BRAFV600E (n ¼ 20) p Value p Value (Dunn’s test)
(Kruskal Wallis test) NT vs BRAF-wt NT vs BRAFV600E BRAF-wt vs BRAFV600E
ECM degradation
COL5A1 1 ± 0.52 13.78 ± 27.56 8.96 ± 14.08 0.0016 <0.05 <0.01 ns
CTSB 1 ± 0.44 1.51 ± 0.82 2.36 ± 0.97 <0.0001 ns <0.001 <0.05
ECM1 1 ± 0.49 39.97 ± 49.66 5.04 ± 7.80 <0.0001 <0.001 <0.01 ns
LAMB3 1 ± 0.88 67.24 ± 53.11 99.83 ± 105.84 <0.0001 <0.001 <0.001 ns
LOX 1 ± 0.52 1.25 ± 1.77 1.56 ± 1.05 ns ns ns ns
LOXL2 1 ± 0.37 5.57 ± 8.05 3.99 ± 3.77 0.0001 <0.01 <0.001 ns
MMP2 1 ± 0.55 0.80 ± 0.82 0.65 ± 0.35 ns ns ns ns
MMP9 1 ± 1.09 7.68 ± 20.99 3.34 ± 3.99 0.038 ns <0.05 ns
PLAU 1 ± 0.45 19.17 ± 20.16 14.86 ± 10.78 <0.0001 <0.001 <0.001 ns
PLAUR 1 ± 0.72 8.43 ± 7.98 7.49 ± 6.20 <0.0001 <0.001 <0.001 ns
TIMP3 1 ± 0.37 1.03 ± 1.02 4.60 ± 16.64 ns ns ns ns
ECM adhesion
CDH1 1 ± 0.54 1.59 ± 1.75 1.84 ± 2.37 ns ns ns ns
CDH2 1 ± 1.46 6.48 ± 5.31 12.90 ± 20.31 0.0002 <0.01 <0.001 ns
CDH11 1 ± 0.45 2.85 ± 4.71 2.53 ± 1.50 0.0032 ns <0.01 ns
CDH16 1 ± 0.65 0.10 ± 0.11 0.05 ± 0.06 <0.0001 <0.001 <0.001 ns
FN1 1 ± 0.49 73.79 ± 101.68 148.33 ± 171.12 <0.0001 <0.05 <0.001 ns
SPP1 1 ± 1.19 2.53 ± 2.51 4.92 ± 4.71 0.0003 ns <0.001 ns
VIM 1 ± 0.41 1.06 ± 0.89 1.20 ± 1.66 ns ns ns ns
Transcription factors
SNAI1 1 ± 0.45 0.87 ± 1.02 0.28 ± 0.15 <0.0001 ns <0.001 <0.05
SNAI2 1 ± 0.66 0.52 ± 0.47 0.38 ± 0.21 0.0006 <0.05 <0.001 ns
SNAI3 1 ± 0.57 3.04 ± 5.27 2.18 ± 2.20 0.0171 ns <0.05 ns
SPRY4 1 ± 0.46 3.48 ± 2.21 2.40 ± 1.85 <0.0001 <0.001 <0.01 ns
STAT3 1 ± 0.47 1.47 ± 1.15 1.97 ± 1.70 0.0112 ns <0.01 ns
TCF3 1 ± 0.45 1.66 ± 1.32 1.70 ± 1.13 ns ns ns ns
TWIST1 1 ± 0.47 1.85 ± 2.46 1.12 ± 0.78 ns ns ns ns
ZEB1 1 ± 0.52 0.69 ± 0.52 0.49 ± 0.23 0.0007 <0.05 <0.001 ns
ZEB2 1 ± 0.51 0.84 ± 0.67 0.68 ± 0.55 0.0429 ns <0.05 ns
ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; ns, not significant; NT, normal thyroid tissues; PTC, papillary thyroid carcinoma; wt, wild type.
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Fig. 1. FN1 mRNA levels in PTCs from the validation group. FN1 mRNA expression in: A. Papillary thyroid carcinoma (PTC) and lymph node (LN) metastases; B. Low risk-PTCs (LR-
PTC), intermediate risk-PTCs (IR-PTC), and normal thyroid tissue (NT); C. BRAF-wild type (BRAF-wt) and BRAFV600E PTCs; D. Follicular-variant PTC (PTC-FV) and classic PTC (PTC-CL).
In A-D, all are compared with normal thyroid tissue (NT). Relative expression levels are reported as means ± SD normalized to values in NT (equal to 1). P values were obtained with
the Kruskal Wallis test followed by Dunn’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant.
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Novel targeted therapies are needed for the 20e30% of PTC
patients who fail to respond to current approaches based on sur-
gery plus radioiodine therapy. Efforts are thus being made to
elucidate the molecular mechanisms underlying the enhanced
aggressiveness of certain PTCs. The lack of responsiveness to radi-
oiodine of recurrent/metastatic PTC lesions is largely the result of
de-differentiation, in particular, the downregulated or abrogatedFig. 2. Expression of FN1 in a subgroup of IR-PTCs from the validation group. Western
blot analysis revealed a band of approximately 250 kDa, corresponding to human FN1
protein, in the total protein extracts from normal (NT) and tumor (PTC) tissues from 9
patients, numbered 1 to 9. Data shown are relative to a representative group of IR-
PTCs. b-actin was used as loading control.expression of a functioning form of the sodium/iodide symporter
(Arturi et al., 2000, 2001; Kogai and Brent, 2012; Schlumberger
et al., 2007). Loss of differentiation, which is usually accompanied
by dysregulated cell proliferation, is the result of genetic and
epigenetic alterations that are characteristic of the more aggressive
PTCs. The identification of some of alterations has led to the
development of novel forms of molecularly targeted therapies for
these tumors, which are currently under investigation (Fagin and
Mitsiades, 2008; Russo et al., 2011, 2013; Xing, 2013; Galr~ao et al.,
2013; Spitzweg et al., 2014; Carneiro et al., 2015). However, more
complete characterization of individual tumors, including clinical,
biological, and molecular features, can also provide valuable
information.
In this study, we first examined the expression of several EMT
markers in a group of 36 PTCs and their relation to ATA risk classes
(Haugen et al., 2016) and BRAFV600E mutational statuses. Consistent
with the view of EMT as a sign of cancer progression (Vasko et al.,
2007), our findings revealed higher levels of almost all the EMT
genes in PTCs characterized by IR rather than LR. Moreover, our
data provide additional information regarding a higher expression
detected in the PTC-CL as opposed to PTC-FV histotypes, and in the
BRAFV600E PTCs compared to BRAF-wt PTCs. These findings were
not surprising. Recent reports have highlighted enormous differ-
ences between the overall gene expression profiles of PTC-CL and
PTC-FV (see the cancer Genome Research Atlas, 2014), and sub-
stantial changes in the ECM have been attributed to mutational
activation of BRAF (Nucera et al., 2011; Riesco-Eizaguirre et al.,
2009; Knauf et al., 2011; Baquero et al., 2013).
Among the EMT markers that we assessed, the most markedly
upregulated gene was FN1. As confirmed in the validation series
(50 PTCs, 6 LNs), the largest PTC-related increases in FN1 mRNA
levels were associated with IR (vs LR), BRAFV600E (vs BRAF-wt), and
PTC-CL vsPTC-FVhistotypes. Thesefindings are fully consistentwith
the TCGA data set (Broad Institute TCGA Genome Data Analysis
Fig. 3. Analysis of FN1 expression in thyroid cancer cells. Effects of FN1 silencing by transfecting three different siRNAs (siFN1 a, b, c) in TPC-1 and BCPAP cells. A. Western blotting
analysis shows different FN1 expression levels in TPC-1 and BCPAP cell lines compared with the non-tumorigenic cell line Nthy-ori-3-1. B. Representative immunoblot from three
different experiments, as described in Materials and methods. Loading control: b-actin. C. Representative immunofluorescence findings in cells transfected with one of the three
siRNAs. FN1 protein was detected with Alexa Fluor 555 conjugated secondary antibody; nuclei were stained with Hoechst 33258. ctrl, control; siCtrl: cells transfected with siRNA
sequence control.
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cations found in a series of aggressive PTCs (Passon et al., 2015).
Gain of fibronectin is one of the defining features of EMT (JungFig. 4. FN1 silencing reduced proliferation of TPC-1 and BCPAP cells. After FN1
silencing, cells were plated and 24 h later viability was evaluated by MTT (upper panel)
and count (lower panel) assays, as described in Materials and methods. Data relative to
siFN1 are expressed as means of results obtained with the three different FN1 siRNAs.
Results show average viability (±SD) of TPC-1 and BCPAP (plated eight or three times
for MTT and count assay, respectively) treated with siRNA sequence control (siCtrl,
white bar) or FN1 siRNAs (siFN1, black bar). Results in figure were obtained from a
single experiment and were confirmed in other two independent experiments. Sta-
tistical analysis was performed using the Tukey-Kramer multiple comparisons test.
*p < 0.05, **p < 0.01.et al., 2015): it alters the composition of the ECM and is believed
to contribute to the invasive properties of cancers. Indeed, many
studies have documented an association between FN1 expression
and the invasive capacities of cells from various cancers, including
those of the ovary, breast, and prostate (Yousif, 2014; Jeon et al.,
2015; Pal et al., 2013). Moreover, several groups described over-
expression of FN1 in thyroid cancer based on analysis of tumor
tissue specimens or fine needle aspiration biopsies (FNAB) (Frykn€as
et al., 2006; Prasad et al., 2005; Rodrigues et al., 2007; Griffith et al.,
2006; Huang et al., 2001). FN1 expression has also been proposed
as molecular marker for identifying malignant lesions among those
with indeterminate FNABs (Fujarewicz et al., 2007; da Silveira
Mitteldorf et al., 2011), and there is even some immunohisto-
chemical evidence that increased FN1 expression is localized
mainly in the invasive front of thyroid cancers (Vasko et al., 2007).
These findings indicate that FN1dlike other EMT-related
proteinsdis a negative prognostic marker in patients with PTC
(Vasko et al., 2007; Montemayor-Garcia et al., 2013). Nonetheless,
an in-depth investigation of its biopathological role in thyroid
cancer has never been undertaken.
To address this issue, we used an in vitro gene silencing
approach in two cell lines carrying the most common genetic al-
terations detected in human PTCs. FN1 silencing was associated
with a significant reduction in the proliferation rate and, more
importantly, decreases in cell adhesion, migration, and invasive
capacities. These effects were observed in both cell lines, but, in
accordance with our in vivo data on BRAFV600E tumors, the
decreased proliferation and migration were particularly evident in
BCPAP cells, which harbor the BRAFV600E mutation, than in the TPC-
1 line. Although themoremarkedly diminishedmigration observed
in BCPAP siFN1 cells might be partly the result of higher intra-assay
cell mortality, the link between FN1 and BRAFV600E mutation is also
supported by the reduced FN1 expression observed in BCPAP cells
after treatment with the BRAF inhibitor PLX4032.
Fig. 5. FN1 expression affects adhesion, migration, and invasiveness of TPC-1 and BCPAP cells. Cells transfected with FN1 specific siRNA (siFN1a, b, or c) or siRNA control sequence
(siCtrl), were prepared for adhesion, migration, and invasion assays as indicated in Materials and methods. For adhesion assays, after 1 h of incubation, cells were fixed, photo-
graphed at 10x magnification, and stained with crystal violet (see Materials and Methods). For migration and invasion assays, after 6 h or 24 h of incubation respectively, filters were
stained, photographed at 10x magnification and cells counted. Data relative to siFN1 are means of the results obtained with the three FN1 specific siRNAs. Values are expressed as
means ± SD from a single experiment, performed in quadruplicate (adhesion) or triplicate (migration and invasion assays). Results were confirmed in two independent experi-
ments. Differences were evaluated with the Tukey-Kramer multiple comparisons test. **p < 0.01, ***p < 0.001.
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teins Snail1, p65NF-kB, and PARP1 occurs to activate the expression
of FN1 in cells undergoing EMT (Stanisavljevic et al., 2011). These
data shed light on the mechanism underlying FN1 overexpression
in PTCs since these tumors are characterized by increased expres-
sion of Snail and p65NF-kB (Hardy et al., 2007; Zhang et al., 2014).
In addition, we have shown that PARP1 inhibition diminishesFig. 6. BRAF inhibition induced a reduction of FN1 expression. BCPAP cells were
treated with the indicated concentrations of PLX4032 for 24 h and FN1 expression was
measured at each concentration as described in Material and methods. BRAF inhibition
was evaluated by western blot analysis of p-ERK. b-actin and ERK were used as loading
control.proliferation and induces differentiation in thyroid cancer cell lines
(Lavarone et al., 2013). These results predict that treatment of PTC
with PARP1 inhibitors might be capable of inhibiting the EMT,
thereby offering benefits for patients withmore aggressive forms of
these tumors.
Finally, our findings demonstrate that FN1 overexpression
characterizes the more aggressive PTCs and may play an important
role during thyroid tumor progression by influencing the migration
and invasion properties of neoplastic cells. Its relationship with
BRAFV600E and PTC-CL may suggest to further investigate FN1 as
molecular target in this selected group of tumors.Acknowledgments
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